Intra-Cellular Therapies, Inc.

NASDAQ (USD): Intra-Cellular Therapies, Inc. (ITCI)

Last Price

127.82

Today's Change

-0.24 (0.18%)

Day's Change

127.79 - 128.169

Trading Volume

1,372,571

Overview

Market Cap

13 Billion

Shares Outstanding

106 Million

Avg Volume

2,475,165

Avg Price (50 Days)

105.05

Avg Price (200 Days)

82.59

PE Ratio

-146.92

EPS

-0.87

Earnings Announcement

20-Feb-2025

Previous Close

128.06

Open

127.95

Day's Range

127.8 - 128.17

Year Range

62.78 - 128.19

Trading Volume

1,382,005

Price Change Highlight

1 Day Change

-0.19%

5 Day Change

0.25%

1 Month Change

1.28%

3 Month Change

53.22%

6 Month Change

70.81%

Ytd Change

51.73%

1 Year Change

73.43%

3 Year Change

122.33%

5 Year Change

433.92%

10 Year Change

399.69%

Max Change

752.13%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Drug Manufacturers—Specialty & Generic

Description:

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment